{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.8","upperLimit":"88.0","value":"81.3"},{"groupId":"OG001","lowerLimit":"78.5","upperLimit":"92.2","value":"86.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"DCR was defined as the percentage of randomized participants who were confirmed to have achieved CR or PR or have a best overall response as stable disease (SD) for 6 weeks or more after initiation of the study drug. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \\<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\\<10mm short axis) and norrmalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD was defined as at least a 20% increase in the sum of diameters of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).","id":"OG000","title":"Brigatinib 90 mg"},{"description":"Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).","id":"OG001","title":"Brigatinib 90 mg - 180 mg"}],"paramType":"NUMBER","populationDescription":"ITT Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhered to the assigned dose.","reportingStatus":"POSTED","timeFrame":"Screening, at 8-week intervals thereafter (on Day 1 of every odd-numbered Cycle of 28-days) through 15 Cycles and every 3 Cycles thereafter until disease progression or up to end of the study (approximately up to 69 months)","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}